FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890888605> ?p ?o ?g. }

• W2890888605 endingPage "738" @default.
• W2890888605 startingPage "731" @default.
• W2890888605 abstract "Discriminating indolent from clinically significant prostate cancer (PCa) in the initial biopsy setting remains an important issue. Prospectively evaluated diagnostic assays are necessary to ensure efficacy and clinical adoption.Performance and utility assessment of ExoDx Prostate (IntelliScore) (EPI) urine exosome gene expression assay versus standard clinical parameters for discriminating Grade Group (GG) ≥2 PCa from GG1 PCa and benign disease on initial biopsy.A two-phase adaptive clinical utility study (NCT03031418) comparing EPI results with biopsy outcomes in men, with age ≥50 yr and prostate-specific antigen (PSA) 2-10ng/ml, scheduled for initial prostate biopsy. After EPI performance assessment during phase I, a clinical implementation document (ie, CarePath) was developed for utilizing the EPI test in phase II, where the biopsy decision is uncertain.Performance evaluation of the EPI test in patients enrolled in phase I and publication of a consensus CarePath for phase II.In a total of 503 patients, with median age of 64 yr, median PSA 5.4ng/ml, 14% African American, 70% Caucasian, 53% positive biopsy rate (22% GG1, 17% GG2, and 15% ≥ GG3), EPI was superior to an optimized model of standard clinical parameters with an area under the curve (AUC) 0.70 versus 0.62, respectively, comparable with previously published results (n=519 patients, EPI AUC 0.71). Validated cut-point 15.6 would avoid 26% of unnecessary prostate biopsies and 20% of total biopsies, with negative predictive value (NPV) 89% and missing 7% of ≥GG2 PCa. Alternative cut-point 20 would avoid 40% of unnecessary biopsies and 31% of total biopsies, with NPV 89% and missing 11% of ≥GG2 PCa. The clinical investigators reached consensus recommending use of the 15.6 cut-point for phase II. Outcome of the decision impact cohort in phase II will be reported separately.EPI is a noninvasive, easy-to-use, gene expression urine assay, which has now been successfully validated in over 1000 patients across two prospective validation trials to stratify risk of ≥GG2 from GG1 cancer and benign disease. The test improves identification of patients with higher grade disease and would reduce the total number of unnecessary biopsies.It is challenging to predict which men are likely to have high-grade prostate cancer (PCa) at initial biopsy with prostate-specific antigen 2-10ng/ml. This study further demonstrates that the ExoDx Prostate (IntelliScore) test can predict ≥GG2 PCa at initial biopsy and defer unnecessary biopsies better than existing risk calculator's and standard clinical data." @default.
• W2890888605 created "2018-09-27" @default.
• W2890888605 creator A5000622048 @default.
• W2890888605 creator A5003167338 @default.
• W2890888605 creator A5005570829 @default.
• W2890888605 creator A5015887484 @default.
• W2890888605 creator A5024321239 @default.
• W2890888605 creator A5038040217 @default.
• W2890888605 creator A5056969058 @default.
• W2890888605 creator A5060409090 @default.
• W2890888605 creator A5063449536 @default.
• W2890888605 creator A5064230008 @default.
• W2890888605 creator A5074341812 @default.
• W2890888605 creator A5074550205 @default.
• W2890888605 creator A5088518998 @default.
• W2890888605 date "2018-12-01" @default.
• W2890888605 modified "2023-10-13" @default.
• W2890888605 title "A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2–10 ng/ml at Initial Biopsy" @default.
• W2890888605 cites W1573867559 @default.
• W2890888605 cites W1850877339 @default.
• W2890888605 cites W1970876554 @default.
• W2890888605 cites W1978950973 @default.
• W2890888605 cites W1982445437 @default.
• W2890888605 cites W2037100502 @default.
• W2890888605 cites W2057615180 @default.
• W2890888605 cites W2088978840 @default.
• W2890888605 cites W2089378422 @default.
• W2890888605 cites W2105019574 @default.
• W2890888605 cites W2119391023 @default.
• W2890888605 cites W2134793522 @default.
• W2890888605 cites W2156992415 @default.
• W2890888605 cites W2162168304 @default.
• W2890888605 cites W2168987885 @default.
• W2890888605 cites W2190525641 @default.
• W2890888605 cites W2297421123 @default.
• W2890888605 cites W2316242722 @default.
• W2890888605 cites W2338026057 @default.
• W2890888605 cites W2548135750 @default.
• W2890888605 cites W2570618306 @default.
• W2890888605 cites W2592285328 @default.
• W2890888605 cites W2742665732 @default.
• W2890888605 cites W2765984831 @default.
• W2890888605 cites W2766011373 @default.
• W2890888605 cites W2767883250 @default.
• W2890888605 cites W2781814793 @default.
• W2890888605 doi "https://doi.org/10.1016/j.eururo.2018.08.019" @default.
• W2890888605 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30237023" @default.
• W2890888605 hasPublicationYear "2018" @default.
• W2890888605 type Work @default.
• W2890888605 sameAs 2890888605 @default.
• W2890888605 citedByCount "163" @default.
• W2890888605 countsByYear W28908886052018 @default.
• W2890888605 countsByYear W28908886052019 @default.
• W2890888605 countsByYear W28908886052020 @default.
• W2890888605 countsByYear W28908886052021 @default.
• W2890888605 countsByYear W28908886052022 @default.
• W2890888605 countsByYear W28908886052023 @default.
• W2890888605 crossrefType "journal-article" @default.
• W2890888605 hasAuthorship W2890888605A5000622048 @default.
• W2890888605 hasAuthorship W2890888605A5003167338 @default.
• W2890888605 hasAuthorship W2890888605A5005570829 @default.
• W2890888605 hasAuthorship W2890888605A5015887484 @default.
• W2890888605 hasAuthorship W2890888605A5024321239 @default.
• W2890888605 hasAuthorship W2890888605A5038040217 @default.
• W2890888605 hasAuthorship W2890888605A5056969058 @default.
• W2890888605 hasAuthorship W2890888605A5060409090 @default.
• W2890888605 hasAuthorship W2890888605A5063449536 @default.
• W2890888605 hasAuthorship W2890888605A5064230008 @default.
• W2890888605 hasAuthorship W2890888605A5074341812 @default.
• W2890888605 hasAuthorship W2890888605A5074550205 @default.
• W2890888605 hasAuthorship W2890888605A5088518998 @default.
• W2890888605 hasBestOaLocation W28908886051 @default.
• W2890888605 hasConcept C104317684 @default.
• W2890888605 hasConcept C121608353 @default.
• W2890888605 hasConcept C126322002 @default.
• W2890888605 hasConcept C126894567 @default.
• W2890888605 hasConcept C143998085 @default.
• W2890888605 hasConcept C145059251 @default.
• W2890888605 hasConcept C185592680 @default.
• W2890888605 hasConcept C188816634 @default.
• W2890888605 hasConcept C203092338 @default.
• W2890888605 hasConcept C20518536 @default.
• W2890888605 hasConcept C2775934546 @default.
• W2890888605 hasConcept C2776235491 @default.
• W2890888605 hasConcept C2780192828 @default.
• W2890888605 hasConcept C2781217009 @default.
• W2890888605 hasConcept C2781261824 @default.
• W2890888605 hasConcept C2781406297 @default.
• W2890888605 hasConcept C535046627 @default.
• W2890888605 hasConcept C55493867 @default.
• W2890888605 hasConcept C71924100 @default.
• W2890888605 hasConcept C87874733 @default.
• W2890888605 hasConceptScore W2890888605C104317684 @default.
• W2890888605 hasConceptScore W2890888605C121608353 @default.
• W2890888605 hasConceptScore W2890888605C126322002 @default.
• W2890888605 hasConceptScore W2890888605C126894567 @default.
• W2890888605 hasConceptScore W2890888605C143998085 @default.
• W2890888605 hasConceptScore W2890888605C145059251 @default.

• next